FOLH1 and neoplasm: Two mCRPC patients with challenging clinical situations and extensive pretreatment were treated with 100 kBq/kg of 225Ac-PSMA-617 at bi-monthly intervals as salvage therapy after the presence of a PSMA-positive tumor phenotype had been validated by 68Ga-PSMA-11 PET/CT [42].